CA3217092A1 - Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors - Google Patents

Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors Download PDF

Info

Publication number
CA3217092A1
CA3217092A1 CA3217092A CA3217092A CA3217092A1 CA 3217092 A1 CA3217092 A1 CA 3217092A1 CA 3217092 A CA3217092 A CA 3217092A CA 3217092 A CA3217092 A CA 3217092A CA 3217092 A1 CA3217092 A1 CA 3217092A1
Authority
CA
Canada
Prior art keywords
cio
egfr
inhibitor
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3217092A
Other languages
English (en)
French (fr)
Inventor
Farbod Shojaei
Jill M. RICONO
Robert Goodenow
Mireille GILLINGS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huyabio International LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3217092A1 publication Critical patent/CA3217092A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3217092A 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors Pending CA3217092A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184697P 2021-05-05 2021-05-05
US63/184,697 2021-05-05
US202263320991P 2022-03-17 2022-03-17
US63/320,991 2022-03-17
PCT/US2022/027693 WO2022235815A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3217092A1 true CA3217092A1 (en) 2022-11-10

Family

ID=83932546

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3217092A Pending CA3217092A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Country Status (8)

Country Link
US (1) US20220370456A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334317A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024516998A (cg-RX-API-DMAC10.html)
AU (1) AU2022270106A1 (cg-RX-API-DMAC10.html)
CA (1) CA3217092A1 (cg-RX-API-DMAC10.html)
IL (1) IL308225A (cg-RX-API-DMAC10.html)
MX (1) MX2023012929A (cg-RX-API-DMAC10.html)
WO (1) WO2022235815A1 (cg-RX-API-DMAC10.html)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
WO2015050345A1 (en) 2013-10-01 2015-04-09 Lg Electronics Inc. Control apparatus for mobile terminal and control method thereof
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
CN117263942A (zh) * 2018-03-21 2023-12-22 传达治疗有限公司 Shp2磷酸酶抑制剂及其使用方法
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药(苏州)有限公司 吡嗪类衍生物及其在抑制shp2中的应用
US11033547B2 (en) * 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2022235822A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
CA3217084A1 (en) * 2021-05-05 2022-11-10 Farbod Shojaei Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Also Published As

Publication number Publication date
AU2022270106A1 (en) 2023-12-14
US20220370456A1 (en) 2022-11-24
WO2022235815A1 (en) 2022-11-10
EP4334317A4 (en) 2025-03-05
MX2023012929A (es) 2023-11-13
EP4334317A1 (en) 2024-03-13
IL308225A (en) 2024-01-01
JP2024516998A (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
US12390469B2 (en) SHP2 inhibitor monotherapy and uses thereof
CN107922431B (zh) Hpk1抑制剂及其使用方法
US20100104567A1 (en) Pharmaceutical composition
EA032509B1 (ru) Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
TW201819380A (zh) 作為抗病毒劑之稠合四環吡啶酮化合物
WO2017146236A1 (ja) Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
TW201938149A (zh) 用於治療癌症的選擇性組蛋白去乙醯酶3 (hdac3)抑制劑及免疫治療劑之組合
JP2023548204A (ja) Cd73阻害剤及びその応用
CA3027035A1 (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
JP2019048822A (ja) Egfr依存性疾患またはegfrファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における2−カルボキサミドシクロアミノウレア誘導体の使用
CN111617078A (zh) 用于疾病治疗和/或预防的药物组合物、方法及其用途
US12097203B2 (en) Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
JP2021512103A (ja) Nampt阻害剤を含む抗体薬物複合体(adcs)
US20230293539A1 (en) Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
CN117677619A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
TW202539662A (zh) 抗腫瘤組合物
CN117642398A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
US20220370456A1 (en) Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors
HK40108830A (en) Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors
HK40108828A (en) Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
ES2956866T3 (es) Inmunomoduladores heterocíclicos como inhibidor del punto de control del pdl1
HK40108829A (en) Shp2 inhibitor monotherapy and uses thereof
US20230097801A1 (en) Methods of increasing cell phagocytosis
JP2020520378A (ja) アスコクロリン誘導体を用いた併用療法
KR20230072446A (ko) 암의 치료를 위한 인돌아민 2,3-디옥시게나아제 저해제와 면역체크포인트 억제제의 상승적 조합

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260430

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260430

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260505

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260505

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260505

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260505

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260505